Document Detail


Multimodality approach in management of malignant pleural mesothelioma.
MedLine Citation:
PMID:  16343925     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Malignant pleural mesothelioma (MPM) is a solid, locally aggressive tumor, which has been closely linked to asbestos exposure. The survival rate without treatment ranges from 4 to 12 months. Response to chemotherapy and radiation is poor, and surgery is the most effective therapy. There are currently 3000 new MPM cases per year in the United States, with the peak incidence in the United States and Europe expected to occur in the year 2020. The prognosis depends on the stage of the tumor at the time of diagnosis, its histological type, lymph node status, and resection margins. While the diagnosis is often delayed, earlier intervention may improve life expectancy. Single-modality therapy has not been effective in changing the natural history of MPM. As a result, multimodality regimens involving surgery with radiation, chemotherapy, or immunotherapy have been initiated. Multiple modality approach has demonstrated favorable outcome, particularly in patients with epithelial histology, negative resection margins and presence of no metastases to extrapleural lymph nodes. Cisplatin and mitomycin have demonstrated modest efficacy in management of distant tumor recurrence. Cisplatin and gemcitabine regimen as well as cisplatin/pemetrexed followed by 54 Gy of adjuvant hemithorax radiation have been reported to improve the outcome.
Authors:
Siyamek Neragi-Miandoab
Related Documents :
9270245 - Intrapericardial administration of cisplatin in treatment of metastatic pericardial inv...
21655995 - A multiple-center phase ii study of weekly docetaxel and oxaliplatin as first-line trea...
24403465 - Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal ...
21843915 - A role for maintenance therapy in managing sarcoma.
22473255 - Advancing resuscitation science.
9072585 - Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplat...
Publication Detail:
Type:  Journal Article; Review     Date:  2005-12-15
Journal Detail:
Title:  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery     Volume:  29     ISSN:  1010-7940     ISO Abbreviation:  Eur J Cardiothorac Surg     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-26     Completed Date:  2006-03-09     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8804069     Medline TA:  Eur J Cardiothorac Surg     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  14-9     Citation Subset:  IM    
Affiliation:
Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Chicago, Stritch School of Medicine, Maywood, IL, USA. sneragi@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Agents / therapeutic use
Cisplatin / therapeutic use
Combined Modality Therapy / methods
Deoxycytidine / analogs & derivatives,  therapeutic use
Drug Therapy, Combination
Genetic Therapy / methods
Humans
Immunotherapy / methods
Mesothelioma / drug therapy,  radiotherapy,  therapy*
Palliative Care / methods
Pleural Neoplasms / drug therapy,  radiotherapy,  therapy*
Thoracic Surgical Procedures / mortality
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 15663-27-1/Cisplatin; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spani...
Next Document:  Hot flushes in breast cancer patients.